The established Treg biology and key learnings from select clinical experiences using unmodified Tregs are reviewed and how the state-of-the-art engineering aims to enhance Treg durability, stability, and specificity are presented.
N. Zammit, Martina Sassone-Corsi, P. Zarin et al.· Frontiers in Immunology· 0 citations
An improved NKG2A engager is reported to selectively inhibit NKG2A⁺ NK cells while avoiding activation of NKG2C⁺ subsets, thereby overcoming a key limitation of the natural ligand HLA-E.
Tingxi Guo, Kaya Epstein, M. Hoover et al.· EMBO Molecular Medicine· 0 citations
Analysis of transcriptomic and flow cytometry analyses and a novel hypoimmune approach improves allogeneic cell persistence by preventing T, B, and NK cell mediated rejection support EngTregs as a potent, stable, and versatile cell therapy platform for autoimmune, inflammatory, and ischemic diseases.
P. Zarin, Gene I. Uenishi, Martina Sassone-Corsi et al.· Journal of Immunology· 0 citations
GNTI-932 is a novel, hypoimmune, antigen-specific, off-the-shelf immunotherapy for restoring tolerance in IBD, designed to be scalable and affordable for widespread use.
Martina Sassone-Corsi, J. Yam, Abigail Doherty et al.· Journal of Immunology· 0 citations
GNTI-350 can safely achieve a durable immune reset and may provide superior therapeutic benefit over CAR-T approaches to patients with B cell—driven autoimmune diseases.
P. Zarin, Chris B. Moore, Travis Drow et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
